Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide with Radiotherapy and ADT in Localized Prostate Cancer
NCT03488810Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2020
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Mar 2020; status: withdrawn.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03488810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488810.